Tag Archives: off-label uses

Pfizer must pay $142M over Neurontin marketing

Drug maker Pfizer violated the Racketeer Influenced and Corrupt Organizations Act by engaging in a fraudulent marketing scheme promoting the epilepsy drug Neurontin for “off-label” uses, the 1st U.S. Circuit Court of Appeals has ruled in affirming judgment.

Read More »

J&J unit settles state Risperdal claims for $181M

Johnson & Johnson has agreed to pay a record $181 million to settle claims brought by New York and 36 other states that the company’s Janssen Pharmaceuticals unit improperly marketed Risperdal and other anti-psychotic drugs for “off-label” uses.

Read More »

Glaxo settles marketing fraud charges for record $3 billion

GlaxoSmithKline has agreed to plead guilty and pay $3 billion to resolve charges that the pharmaceutical giant fraudulently marketed the prescription drugs Paxil, Wellbutrin and Avandia, the U.S. Justice Department has announced.

Read More »